Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a vast diversity of intracellular targets that are considered intractable by current drug formats.
Conventional drug formats, such as antibodies or small chemicals, can only address a limited number of all known disease targets. Complix believes that its ability to access the intracellular space with a high affinity protein biologic will allow for the development of an entirely novel class of effective therapeutics.
Complix is developing a transformative pipeline of CPABs primarily addressing intracellular oncogenic targets that play an important role in cancer development and progression.
The Company is currently running multiple in-house CPAB programs based on selection from a diverse collection of undruggable targets, two of which are being developed in partnership with Merck & Co.
Cell Penetrating Alphabodies are transformative biotherapeutics created to address intracellular oncogenic targets that are “undruggable” by existing therapeutics…
Complix’s drug development is initially focused on cancer and autoimmune disease, therapeutic areas that represent a significant opportunity for new therapeutic interventions based on addressing intracellular targets.